Curium Confirms No Supply Challenges in North America and Europe for Its Eclipse Phase III Clinical Trial
Curium confirmed that the company has no foreseeable supply challenges of 177Lu-PSMA-I&T for the company’s ECLIPSE Phase III clinical trial ongoing in the USA, France, Spain, and Italy.
[89bio, Inc.] 89bio, Inc. announced positive topline data from the Phase IIb ENLIVEN trial evaluating treatment with pegozafermin in patients with NASH. In the study, both the 44mg Q2W and 30mg QW doses met, with high statistical significance.
[Communications Biology] The expression of myocardial infarction-associated transcript (MIAT) was up-regulated during liver fibrosis. Silencing MIAT led to the suppression of hepatic stellate cell proliferation and collagen expression.
[EMBO Molecular Medicine] WD-repeat 6 (WDR6) deficiency in hepa1-6 cells drastically inhibited the growth and lung metastasis of orthotopically implanted tumors in immune-competent C57BL/6J mice.